© 2023 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
The price cut came as CMS begins to weight whether Medicare should cover Biogen's controversial Alzheimer's disease drug.
Biogen announced on Monday that it was cutting the price of Aduhelm (aducanumab) in half, from an annual cost of $56,000 to $28,200. Here are five things you should know about the drug and the company’s decisions:
Biogen said it is launching a trial of Aduhelm in May that will enroll 1,300 people with early Alzheimer’s, Stat reported last week. When the FDA approved Aduhelm in June, the agency made the approval contingent upon a confirmatory trial verifying its effectiveness.
More than a dozen prominent Alzheimer’s experts and other well-regarded healthcare professional issued a statement on Monday calling on the FDA to withdraw its approval of Aduhelm. Meanwhile, a group called the Right Care Alliance says it is planning to file a citizen’s petition with the agency to ask that Aduhelm be taken off the market.